GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » cbdMD Inc (AMEX:YCBD) » Definitions » Gross-Profit-to-Asset %

cbdMD (YCBD) Gross-Profit-to-Asset % : 122.98% (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is cbdMD Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. cbdMD's annualized Gross Profit for the quarter that ended in Dec. 2024 was $13.60 Mil. cbdMD's average Total Assets over the quarter that ended in Dec. 2024 was $11.06 Mil. Therefore, cbdMD's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 122.98%.


cbdMD Gross-Profit-to-Asset % Historical Data

The historical data trend for cbdMD's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

cbdMD Gross-Profit-to-Asset % Chart

cbdMD Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.68 25.44 26.96 52.57 89.60

cbdMD Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.94 69.65 95.91 80.38 122.98

Competitive Comparison of cbdMD's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, cbdMD's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


cbdMD's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, cbdMD's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where cbdMD's Gross-Profit-to-Asset % falls into.



cbdMD Gross-Profit-to-Asset % Calculation

cbdMD's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Sep. 2024 )/( (Total Assets (A: Sep. 2023 )+Total Assets (A: Sep. 2024 ))/ count )
=11.996/( (16.195+10.581)/ 2 )
=11.996/13.388
=89.60 %

cbdMD's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=13.604/( (10.581+11.543)/ 2 )
=13.604/11.062
=122.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


cbdMD Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of cbdMD's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


cbdMD Business Description

Traded in Other Exchanges
Address
2101 Westinghouse Boulevard, Suite A, Charlotte, NC, USA, 28273
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
Executives
Thomas Ronan Kennedy officer: Interim CEO and CFO 8845 RED OAK BLVD, CHARLOTTE NC 28217
Bakari T. Sellers director 4231 VOORHEES ROAD, DENMARK SC 29042
Raines William F Iii director 8314 TOSOMOCK LANE, HUNTERSVILLE NC 28078
Scott G. Stephen director 4249 NORTH WINCHESTER AVE., CHICAGO IL 60613
Sibyl Nichole Swift director 730 HAWTHORNE LANE, APT 441, CHARLOTTE NC 28204
Kevin Macdermott officer: President 9580 CALDWELL RD, MOUNT ULLA NC 28125
Wiesehan John J Iii officer: Chief Revenue Officer 8845 RED OAK BOULEVARD, CHARLOTTE NC 28217
Sim Farar director 8845 RED OAK BOULEVARD, CHARLOTTE NC 28217
Martin A. Sumichrast director, officer: Chairman of the Board and CEO 11125 COLONIAL COUNTRY LANE, CHARLOTTE NC 28277
Raymond Scott Coffman director 230 S. TRYON ST., #1302, CHARLOTTE NC 28202
Peter J. Ghiloni director 115 DEER ESTATES LANE, PONTE VEDRA BEACH FL 32082
Mark S Elliott officer: CFO & COO C/O LEVEL BRANDS, INC., 4521 SHARON ROAD, SUITE 450, CHARLOTTE NC 28211
Gregory C Morris director 421 CRANBORNE CHASE, FORT MILL SC 29708
Caryn Nicole Dunayer officer: President 8476 CATAWBA DOVE DR., BELMONT NC 28012
Erik Sterling 10 percent owner 5505 KALANIANAOLE HWY, HONOLULU HI 96821

cbdMD Headlines